Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

Core Insights - Royal Philips announced results from the iMODERN trial, which evaluated the safety and effectiveness of immediate versus delayed treatment of additional narrowed arteries in heart attack patients [1][3][5] - The study found no significant difference in major outcomes between immediate treatment during the first procedure and staged treatment, providing evidence for both approaches [3][5][8] Group 1: Study Overview - The iMODERN trial is the largest study to date testing the instantaneous wave-free ratio (iFR) in acute heart attack settings, involving 1,146 patients across 41 hospitals in 14 countries [5][11] - Patients were randomly assigned to either immediate treatment using iFR or staged treatment guided by cardiac MRI within four days to six weeks after the heart attack [5][6] - The main endpoint combined outcomes of death, repeat heart attack, or hospitalization for heart failure over three years, showing no significant differences between the two treatment strategies [5][6] Group 2: Clinical Implications - The findings confirm that immediate treatment of additional arteries can be safely performed during the first procedure, allowing for a complete solution in one session when appropriate [3][5][8] - The results support current international guidelines recommending complete revascularization in STEMI patients, integrating physiological assessment for tailored treatment [8][9] - The study emphasizes the importance of flexibility in treatment decisions, allowing physicians to tailor approaches based on individual patient needs [6][8] Group 3: Related Studies - Complementary findings from the ILIAS ANOCA study demonstrated the benefits of physiology-guided decision-making in patients with angina and no obstructive coronary arteries, highlighting the value of coronary function testing [9][10] - The ILIAS ANOCA study showed significant improvements in patient-reported angina symptoms and quality of life with tailored therapy, reinforcing the role of Philips technology in guiding individualized treatment strategies [10][11]